ELTP Conference Call 06/30/11

ELPT Milestones

As covered previously, here's a breakdown of what's been happening.  Many feel there is a major need to get some news flowing.  It's a waiting game, but fortunately interest in the stock has yet to wane.  Stay tuned, because when news rains, it usually flows from the ELTP headquarters.  Make sure you are positioned.
Aug 16, 2011 Elite Reports Revenue Of $1m In Q1 Fiscal 2011
Jun 30, 2011 Elite Pharmaceuticals Reports Total Revenue Of $4.3m For Fiscal 2011
Jun 06, 2011 Elite Pharmaceuticals Announces Manufacturing And Supply Agreement 
With Mikah Pharma
Mar 17, 2011 Elite Pharmaceuticals Announces Settlement Of Litigation 
With ThePharmaNetwork
Mar 04, 2011 FDA Action Affects Products Manufactured By Elite Pharmaceuticals

ELTP's Strong Leadership

Here is a recent article discussing how ELTP is fighting FDA adversity by staying close to their strategy and not giving up. When the FDA slammed the door on Lodrane products, they did leave a key available for when required changes were concluded. ELTP struggled through and has now re-released their Lodrane product. From the article:

Their ability to find a solution to a pressing problem is impressive to say the least and recognizing that the current U.S. allergy market exceeds $3.5 billion ELTP knew they had to find their way back onto the shelf. It shouldn’t be lost on investors that given the removal of so many cough/cold allergy related products from the U.S. market the quick turnaround by ELTP and ECR now makes Lodrane D one of the only adult brompheniramine containing products available to the consumer.

Read the rest HERE.

Recent Elite PRs

9/27/2011	ELITE PHARMACEUTICALS AND ECR PHARMACEUTICALS LAUNCH LODRANE D® ALLERGY PRODUCT
8/16/2011	Elite Pharmaceuticals, Inc. Reports Financial Results for the  First Quarter Ended June 30, 2011 Revenues up 19% - Positive Operating Cash Flow – Phentermine Launched
6/30/2011	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal  Year Ended March 31, 2011 Revenues up 28% - Positive Cash Flow – Lodrane Discontinued
6/6/2011	ELITE PHARMACEUTICALS ANNOUNCES MANUFACTURING  AND SUPPLY AGREEMENT WITH MIKAH PHARMA, LLC
4/6/2011	ELITE PHARMACEUTICALS, INC. ANNOUNCES THIRD CLOSING OF STRATEGIC ALLIANCE AGREEMENT WITH EPIC PHARMA

CNN Money LOVES Elite Pharmaceuticals Inc

The 2 analysts for CNN are offering 12-month price forecasts for Elite Pharmaceuticals Inc have a median target of 4.25, with a high estimate of 4.50 and a low estimate of 4.00. The median estimate represents a +4,421.28% increase from the last price of 0.09.

CNN MONEY + ELTP